Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04448886 |
| Title | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Sara Tolaney |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | United States | Details | |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| DFCI @ Foxborough | Foxborough | Massachusetts | 02035 | United States | Details | |
| DFCI @ Milford Regional Hospital | Milford | Massachusetts | 01757 | United States | Details | |
| DF/BWCC in Clinical Affiliation with South Shore Hospital | South Weymouth | Massachusetts | 02190 | United States | Details | |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | United States | Details | |
| University of Pennsylvania-Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | United States | Details |